https://www.gov.uk/government/news/mhra-approves-remibrutinib-for-adults-with-chronic-spontaneous-ur

FDA approves Novartis' Pluvicto for earlier-stage metastatic prostate cancer, nearly doubling el

Axiom Investment Management LLC purchased a new stake in shares of Novartis AG (NYSE: NVS) in the fi

Ashton Thomas Securities LLC purchased a new stake in Novartis AG (NYSE: NVS) during the undefined q

These companies' recent headwinds shouldn't lead to decreased payouts.

Entropy Technologies LP acquired a new position in shares of Novartis AG (NYSE: NVS) in the undefine

Cetera Investment Advisers grew its position in shares of Novartis AG (NYSE: NVS) by 13.5% in the fi

Novartis AG ended Q2 on a high note. Despite declining sales of Entresto, the heart failure medicine

Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.

Novartis AG (NVS) Q2 2026 Earnings Call Transcript

Novartis reported better-than-expected sales and earnings for the second quarter, driven by strong p

Novartis tops Q2 earnings and revenue estimates as growth from key brands offsets generic pressure,

GM, MMM, NVS, NOC, HAS and DHI all outperformed expectations on their quarterly reports this morning

Novartis NYSE: NVS said it returned to sales growth in the second quarter of 2026, supported by stro

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the qu

Novartis (NYSE:NVS) reported second-quarter financial results on Tuesday. The transcript from the co

Stock futures are rising after three straight days of declines for major indexes; chip stocks are le

Novartis AG (NYSE:NVS) reported better-than-expected second-quarter earnings on Tuesday as strong de

Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats

Novartis chief executive ​officer Vas Narasimhan ‌said on Tuesday he plans ​to stick ​around for the

Companies Reporting Before The Bell • Mueller Industries (NYSE:MLI) is projected to report quarterly

Novartis beat market expectations for second-quarter core operating profit on Tuesday. Lower-than-ex

Second-quarter net sales rose 1% at constant currency as growth from some of its top-selling product

Novartis' second-quarter core operating profit beat ​market expectations on Tuesday, ‌helped by stro

Novartis (NYSE:NVS) reported quarterly earnings of $2.41 per share which beat the analyst consensus

Novartis delivered a solid second quarter, returning to sales growth driven by continued momentum fr

While the first quarter showed weaker revenue and earnings, management had already warned that 2026

Novartis wins traditional FDA approval for Fabhalta, a first-in-class oral treatment slowing kidney

IgAN is an autoimmune kidney disease that occurs when clumps of immunoglobulin A and antibodies are

Elizabeth Warren warns Trump's law pushed children off Medicaid and CHIP in many states, while a

Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with

Supreme Court lets Medicare drug price negotiations continue, rejecting pharma industry challenges t

The US Supreme Court turned away appeals from six pharmaceutical companies seeking to topple the Med

White House estimates Trump's drug pricing agreements could save $529 billion in next decade, bu

Sen. Warren challenges Trump's 600% TrumpRx drug price claim using a glass of water.

Novartis' RemIND trial shows oral remibrutinib offers breakthrough relief for chronic urticaria

International ETFs are gaining momentum as global markets outperform US stocks. Here's what'

The complete list of Super Bowl 2026 commercials from Super Bowl LX and the companies behind the ads

CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding t

Enliven Therapeutics' stock rose after early trial results showed strong responses and good safe

Accenture to acquire UK-based AI firm Faculty, adding 400 specialists and decision intelligence capa

Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfr

Terns Pharma presented positive data from ongoing CARDINAL trial of TERN-701 in CML patients, showin

U.S. companies have struck more than $80 billion worth of deals in the past 24 hours, in the latest

President Donald Trump announced a barrage of new tariffs on Thursday, aimed at pharmaceuticals, hea